Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver G Ottmann

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Blood|October 2, 2004
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the diseaseWalter Fiedler, Hubert Serve, Hartmut Döhner, et al.
Blood|August 30, 2002
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemiasOliver G Ottmann, Brian J Druker, Charles L Sawyers, et al.
Blood|April 28, 2006
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)Barbara Wassmann, Heike Pfeifer, Nicola Goekbuget, et al.
Blood|January 20, 2018
Genomic CDKN2A/2B deletions in adult Ph<sup>+</sup> ALL are adverse despite allogeneic stem cell transplantationHeike Pfeifer, Katharina Raum, Sandra Markovic, et al.
Blood|November 25, 2010
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsHagop M Kantarjian, Francis J Giles, Kapil N Bhalla, et al.
Blood|December 1, 2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemiaPhilipp le Coutre, Oliver G Ottmann, Francis Giles, et al.
Blood|March 6, 2002
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyMoshe Talpaz, Richard T Silver, Brian J Druker, et al.
Blood|October 2, 2012
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLMax S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.
American Journal of Hematology|November 23, 2023
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromesAndrew M Brunner, Jordi Esteve, Kimmo Porkka, et al.
Hemasphere|August 5, 2021
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 TrialHartmut Döhner, Argiris Symeonidis, Dries Deeren, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Blood|October 2, 2004
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the diseaseWalter Fiedler, Hubert Serve, Hartmut Döhner, et al.
Blood|August 30, 2002
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemiasOliver G Ottmann, Brian J Druker, Charles L Sawyers, et al.
Blood|April 28, 2006
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)Barbara Wassmann, Heike Pfeifer, Nicola Goekbuget, et al.
Blood|January 20, 2018
Genomic CDKN2A/2B deletions in adult Ph<sup>+</sup> ALL are adverse despite allogeneic stem cell transplantationHeike Pfeifer, Katharina Raum, Sandra Markovic, et al.
Blood|November 25, 2010
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsHagop M Kantarjian, Francis J Giles, Kapil N Bhalla, et al.
Blood|December 1, 2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemiaPhilipp le Coutre, Oliver G Ottmann, Francis Giles, et al.
Blood|March 6, 2002
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyMoshe Talpaz, Richard T Silver, Brian J Druker, et al.
Blood|October 2, 2012
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLMax S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.
American Journal of Hematology|November 23, 2023
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromesAndrew M Brunner, Jordi Esteve, Kimmo Porkka, et al.
Hemasphere|August 5, 2021
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 TrialHartmut Döhner, Argiris Symeonidis, Dries Deeren, et al.
Pageof 11